Skip to contentA
Amphastar Pharmaceuticals, Inc.
A
AMPHAmphastar Pharmaceuticals, Inc. Q1 2024 · 10-Q
Revenue$171.84M$171.84M+22.7% vs Q1 2023 Net Income$43.18M$43.18M+65.9% vs Q1 2023 EPS Diluted$0.81$0.81+62.0% vs Q1 2023 Gross Profit$90,100,000+22.0% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Amphastar Pharmaceuticals, Inc. · CIK 1297184 · Engraved from SEC EDGAR
Operating Cash Flow$55,291,000+36.9% Free Cash Flowderived$46,498,000+50.5% Margins · derivedGross margin52.4%−0.3 pt vs Q1 2023
Operating margin27.9%+4.1 pt vs Q1 2023
Net margin25.1%+6.5 pt vs Q1 2023
ended Mar 31, 2024 · filed May 10, 2024 · 40 d after period end